Zymeworks (NYSE: ZYME) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Zymeworks to related businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.
This table compares Zymeworks and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares Zymeworks and its peers gross revenue, earnings per share (EPS) and valuation.
Zymeworks’ peers have higher revenue and earnings than Zymeworks.
Institutional & Insider Ownership
7.3% of Zymeworks shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings for Zymeworks and its peers, as provided by MarketBeat.
||Strong Buy Ratings
Zymeworks presently has a consensus price target of $16.00, indicating a potential upside of 53.70%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.24%. Given Zymeworks’ higher probable upside, analysts plainly believe Zymeworks is more favorable than its peers.
Zymeworks peers beat Zymeworks on 9 of the 11 factors compared.
Zymeworks Company Profile
Zymeworks Inc is a Canada-based biopharmaceutical company. The Company specializes in the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The Company operates through a number of platforms, including Azymetric platform, which is developed for the development of IgG-like, novel bispecific antibodies for the targeting of synergistic drug targets; Albucore platform, which is developed as a flexible and alternative platform to antibodies where it is advantageous for multi-valent therapeutic to target multiple disease targets; Effect, which comprises a library of Fc modifications that can selectively modulate the activity of recruited immune cells, and the ZymeLink Conjugation platform, which is a suite of novel protein site-specific conjugation technologies and customizable cleavable and non-cleavable linkers that is compatible with a variety of small molecule therapeutics.
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.